当前位置: X-MOL 学术Mol. Ther. Oncolytics › 论文详情
microRNA modification of Coxsackievirus B3 decreases its toxicity, while retaining oncolytic potency against lung cancer
Molecular Therapy - Oncolytics ( IF 5.710 ) Pub Date : 2020-01-21 , DOI: 10.1016/j.omto.2020.01.002
Huitao Liu; YuanChao Xue; Haoyu Deng; Yasir Mohamud; ChenSeng Ng; Axel Chu; Chinten James Lim; William W. Lockwood; William W.G. Jia; Honglin Luo

We recently discovered that coxsackievirus B3 (CVB3) is a potent oncolytic virus against KRAS-mutant lung adenocarcinoma. Nevertheless, the evident toxicity restricts the use of wild-type (WT)-CVB3 for cancer therapy. The current study aims to engineer the CVB3 to decrease its toxicity and to extend our previous research to determine its safety and efficacy in treating TP53/RB1-mutant small cell lung cancer (SCLC). A microRNA-modified CVB3 (miR-CVB3) was generated via inserting multiple copies of tumor-suppressive miR-145/miR-143 target sequences into the viral genome. In vitro experiments revealed that miR-CVB3 retained the ability to infect and lyse KRAS-mutant lung adenocarcinoma and TP53/RB1-mutant SCLC cells, but with a markedly reduced cytotoxicity towards cardiomyocytes. In vivo study using a TP53/RB1-mutant SCLC xenograft model demonstrated that a single dose of miR-CVB3 via systemic administration resulted in a significant tumor regression. Most strikingly, mice treated with miR-CVB3 exhibited greatly attenuated cardiotoxicities and decreased viral titers compared to WT-CVB3-treated mice. Collectively, we generated a recombinant CVB3 that is powerful in destroying both KRAS-mutant lung adenocarcinoma and TP53/RB1-mutant SCLC, with a negligible toxicity towards normal tissues. Future investigation is needed to address the issue of genome instability of miR-CVB3, which was observed in ∼40% of mice after a prolonged treatment.
更新日期:2020-01-21

 

全部期刊列表>>
化学/材料学中国作者研究精选
ACS材料视界
南京大学
自然科研论文编辑服务
剑桥大学-
中国科学院大学化学科学学院
南开大学化学院周其林
课题组网站
X-MOL
北京大学分子工程苏南研究院
华东师范大学分子机器及功能材料
中山大学化学工程与技术学院
试剂库存
天合科研
down
wechat
bug